FDC Limited has announced its financial results for the fourth quarter and year ended March 31, 2026, showcasing significant growth across its business segments. The company’s consolidated revenue from operations for Q4 FY26 stood at ₹585 crores, marking an 18.9% year-on-year increase. This robust growth was driven by substantial gains in the Export Formulations and API segments.
The Domestic Formulations business reported a revenue of ₹452 crores in Q4 FY26, reflecting an 8.5% growth year-on-year. However, the annual growth for FY26 was relatively muted at 0.1%, with sales reaching ₹1,781 crores. The subdued performance in top brands like Zifi, Electral, and Enerzal contributed to this slight increase.
Export Formulations experienced remarkable growth, with Q4 FY26 sales reaching ₹89 crores, a 99.3% increase year-on-year. For the full fiscal year, Export Formulations sales totalled ₹260 crores, up by 23.5% compared to the previous year. The US market, in particular, showed strong performance, with revenue from supplies reaching ₹71 crores, a 165.1% year-on-year increase, driven by improved execution and demand momentum.
The API segment also demonstrated strong growth, with Q4 FY26 sales at ₹42 crores, a 38.6% increase year-on-year. For FY26, the API business recorded sales of ₹121 crores, marking an 8.5% growth.
FDC’s EBITDA for Q4 FY26 was ₹106 crores, with margins improving to 18.2% from 11.0% in the previous year, supported by enhanced operational efficiencies. The FY26 EBITDA margin improved to 15.9% from 15.4% year-on-year due to higher gross margins.
During the quarter, FDC received U.S. FDA approval for Fluconazole Tablets USP in various dosages, further strengthening its position in the export market.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).